Y-mAbs Therapeutics Inc. Unveils Presentation on Innovative Oncology Leadership and Therapeutic Platforms

Reuters07-25

Y-mAbs <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc. Unveils Presentation on Innovative Oncology Leadership and Therapeutic Platforms

Y-mAbs Therapeutics Inc., a commercial biopharmaceutical company, has unveiled a corporate presentation highlighting its oncology leadership in pretargeted radioimmunotherapy and antibody-based therapies. The company operates two distinct business units: DANYELZA, focusing on anti-GD2 therapy approved for relapsed/refractory high-risk neuroblastoma, and Radiopharmaceuticals. The presentation emphasizes Y-mAbs' established commercial capabilities, radiopharmaceutical leadership, and a broad pipeline potential. It introduces the Self-Assembly DisAssembly Pretargeted Radioimmunotherapy (SADA PRIT) Platform, showcasing a novel technology with a proven mechanism of pretargeted approach that holds therapeutic potential beyond oncology. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Y-mAbs Therapeutics Inc. published the original content used to generate this news brief on July 24, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2554782789?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-25 01:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2554782789","market":"fut","top_or_hot":-1,"title":"Y-mAbs Therapeutics Inc. Unveils Presentation on Innovative Oncology Leadership and Therapeutic Platforms","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Y-mAbs <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. Unveils Presentation on Innovative Oncology Leadership and Therapeutic Platforms\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Y-mAbs Therapeutics Inc., a commercial biopharmaceutical company, has unveiled a corporate presentation highlighting its oncology leadership in pretargeted radioimmunotherapy and antibody-based therapies. The company operates two distinct business units: DANYELZA, focusing on anti-GD2 therapy approved for relapsed/refractory high-risk neuroblastoma, and Radiopharmaceuticals. The presentation emphasizes Y-mAbs' established commercial capabilities, radiopharmaceutical leadership, and a broad pipeline potential. It introduces the Self-Assembly DisAssembly Pretargeted Radioimmunotherapy (SADA PRIT) Platform, showcasing a novel technology with a proven mechanism of pretargeted approach that holds therapeutic potential beyond oncology. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Y-mAbs Therapeutics Inc. published the original content used to generate this news brief on July 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Y-mAbs Therapeutics Inc. Unveils Presentation on Innovative Oncology Leadership and Therapeutic Platforms</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nY-mAbs Therapeutics Inc. Unveils Presentation on Innovative Oncology Leadership and Therapeutic Platforms\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-25 01:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Y-mAbs <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. Unveils Presentation on Innovative Oncology Leadership and Therapeutic Platforms\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Y-mAbs Therapeutics Inc., a commercial biopharmaceutical company, has unveiled a corporate presentation highlighting its oncology leadership in pretargeted radioimmunotherapy and antibody-based therapies. The company operates two distinct business units: DANYELZA, focusing on anti-GD2 therapy approved for relapsed/refractory high-risk neuroblastoma, and Radiopharmaceuticals. The presentation emphasizes Y-mAbs' established commercial capabilities, radiopharmaceutical leadership, and a broad pipeline potential. It introduces the Self-Assembly DisAssembly Pretargeted Radioimmunotherapy (SADA PRIT) Platform, showcasing a novel technology with a proven mechanism of pretargeted approach that holds therapeutic potential beyond oncology. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Y-mAbs Therapeutics Inc. published the original content used to generate this news brief on July 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250724:nNDL602PCQ:1","article_id":"2554782789","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2554782789","pubTimestamp":1753379117,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Y-mAbs Therapeutics Inc. published the original content used to generate this news brief on July 24, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","YMAB":"Y-mAbs Therapeutics, Inc."},"translate_title":"Y-mAbs Therapeutics Inc.推出创新肿瘤学领导力和治疗平台演示","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"YMAB":0.9},"content_text":"Y-mAbs Therapeutics Inc. Unveils Presentation on Innovative Oncology Leadership and Therapeutic Platforms\n    \n\n        Y-mAbs Therapeutics Inc., a commercial biopharmaceutical company, has unveiled a corporate presentation highlighting its oncology leadership in pretargeted radioimmunotherapy and antibody-based therapies. The company operates two distinct business units: DANYELZA, focusing on anti-GD2 therapy approved for relapsed/refractory high-risk neuroblastoma, and Radiopharmaceuticals. The presentation emphasizes Y-mAbs' established commercial capabilities, radiopharmaceutical leadership, and a broad pipeline potential. It introduces the Self-Assembly DisAssembly Pretargeted Radioimmunotherapy (SADA PRIT) Platform, showcasing a novel technology with a proven mechanism of pretargeted approach that holds therapeutic potential beyond oncology. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Y-mAbs Therapeutics Inc. published the original content used to generate this news brief on July 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2554782789","isCrawlerRequest":true}